tbuckley/cabot-search huggingface dataset:
Reconstruction of the human blood–brain barrier in vitro reveals a pathogenic mechanism of APOE4 in pericytes
Authors: Joel W. Blanchard, Michael Bula, Jose Davila-Velderrain, Leyla Anne Akay, Lena Zhu, Alexander Frank, Matheus B. Victor, Julia Maeve Bonner, Hansruedi Mathys, Yuan-Ta Lin, Tak Ko, David A. Bennett, Hugh P. Cam, Manolis Kellis, Li-Huei Tsai
Journal: Nature Medicine (2020)
Response by Cohen et al to Letter Regarding Article, “Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19”
Authors: Jordana B. Cohen, Thomas C. Hanff, Andrew M. South, Matthew A. Sparks, Swapnil Hiremath, Adam P. Bress, J. Brian Byrd, Julio A. Chirinos
Journal: Circulation Research (2020)
Abstract B35: Isolation and characterization of circulating tumor cells (CTCs) from bladder cancer patients using a highly sensitive graphene oxide-based microfluidic device (GO chip)
Authors: Zeqi Niu, Molly A. Kozminsky, Kathleen C. Day, Phillip L. Palmbos, Mark L. Day, Sunitha Nagrath
Journal: Clinical Cancer Research (2020)

Abstract Introduction: A critical research topic in bladder cancer is determining the key regulators in the progression from noninvasive tumor to invasive and ultimately metastatic disease. Although patients with noninvasive bladder cancer can be treated through transurethral resection of bladder tumor and have a high survival rate (~95%), noninvasive bladder tumors recur in 50%-70% of cases. Of these, 10-15% of cases progress to invasive disease. Circulating tumor cells (CTCs) represent the transitional phase of progression between lymphovascular intravasation and distant metastases. Molecular profiling of these CTCs, beyond enumeration, can inform the molecules/pathways important in the invasion process, and potentially help unravel the mechanism of metastasis and provide new targets for therapy. Here we report the application of a highly sensitive graphene oxide-based microfluidic device to isolate and characterize CTCs from bladder cancer patients for the expression of markers implicated in an invasive phenotype. Methods: An anti-EpCAM and anti-EGFR biotinylated antibody cocktail was immobilized onto the graphene oxide chip (GO chip) to capture CTCs from whole blood. In patient samples, immunofluorescence staining for DAPI (nuclei), cytokeratin (cancer cell marker), EGFR and HER2 (markers of invasive phenotype), and CD45 (white blood cell marker) was used to enumerate CTCs. Cells with a DAPI+CK+CD45- phenotype were counted as CTCs. Blood samples from ten metastatic bladder cancer patients and two healthy controls were processed, stained, and analyzed. Results: CTCs were found in 10/10 (100%) patients, with an average of 17.70 cells/mL (s = 10.69 cells/mL). 9/10 patients exhibited CTCs that express EGFR, but only one patient had one CTC express HER2. Conclusion: The antibody-functionalized GO chips were able to successfully capture and enable characterization of CTCs from metastatic bladder cancer patients. EGFR potentially plays an important role in the vascular invasion process. Citation Format: Zeqi Niu, Molly A. Kozminsky, Kathleen C. Day, Phillip L. Palmbos, Mark L. Day, Sunitha Nagrath. Isolation and characterization of circulating tumor cells (CTCs) from bladder cancer patients using a highly sensitive graphene oxide-based microfluidic device (GO chip) [abstract]. In: Proceedings of the AACR Special Conference on Advances in Liquid Biopsies; Jan 13-16, 2020; Miami, FL. Philadelphia (PA): AACR; Clin Cancer Res 2020;26(11_Suppl):Abstract nr B35.
COVID-19 diagnostics—not at the expense of other diseases
Authors: Priya Venkatesan
Journal: The Lancet Microbe (2020)

The 2020 COVID-19 pandemic shows no signs of abating, with WHO reporting 4·9 million cases and 322 000 deaths globally as of May 21, 2020. What also shows no sign of abating is the ferocious reactive response to the pandemic—academic institutions, pharmaceutical companies, and governments alike have turned almost their whole focus to COVID-19 research, causing many health-care experts to fear that the management of other deadly diseases has been relegated to a much lower priority. The intense focus on COVID-19 might hinder the efforts and undo progress made in controlling other infectious diseases.
Renal Denervation in High-Risk Patients With Hypertension
Authors: Felix Mahfoud, Giuseppe Mancia, Roland Schmieder, Krzysztof Narkiewicz, Luis Ruilope, Markus Schlaich, Robert Whitbourn, Andreas Zirlik, Thomas Zeller, Philipp Stawowy, Sidney A. Cohen, Martin Fahy, Michael Böhm
Journal: Journal of the American College of Cardiology (2020)

Renal denervation (RDN) is under investigation for treatment of uncontrolled hypertension and might represent an attractive treatment for patients with high cardiovascular (CV) risk. It is important to determine whether baseline CV risk affects the efficacy of RDN. The purpose of this study was to assess blood pressure (BP) reduction and event rates after RDN in patients with various comorbidities, testing the hypothesis that RDN is effective and durable in these high-risk populations. BP reduction and adverse events over 3 years were evaluated for several high-risk subgroups in the GSR (Global proSpective registrY for syMPathetic renaL denervatIon in seleCted IndicatIons Through 3 Years Registry), an international registry of RDN in patients with uncontrolled hypertension (n = 2,652). Comparisons were made for patients age ≥65 years versus age <65 years, with versus without isolated systolic hypertension, with versus without atrial fibrillation, and with versus without diabetes mellitus. Baseline cardiovascular risk was estimated using the American Heart Association (AHA)/American College of Cardiology (ACC) atherosclerosis cardiovascular disease (ASCVD) risk score. Reduction in 24-h systolic BP at 3 years was −8.9 ± 20.1 mm Hg for the overall cohort, and for high-risk subgroups, BP reduction was −10.4 ± 21.0 mm Hg for resistant hypertension, −8.7 ± 17.4 mm Hg in patients age ≥65 years, −10.2 ± 17.9 mm Hg in patients with diabetes, −8.6 ± 18.7 mm Hg in isolated systolic hypertension, −10.1 ± 20.3 mm Hg in chronic kidney disease, and −10.0 ± 19.1 mm Hg in atrial fibrillation (p < 0.0001 compared with baseline for all). BP reduction in patients with measurements at 6, 12, 24, and 36 months showed similar reductions in office and 24-h BP for patients with varying baseline ASCVD risk scores, which was sustained to 3 years. Adverse event rates at 3 years were higher for patients with higher baseline CV risk. BP reduction after RDN was similar for patients with varying high-risk comorbidities and across the range of ASCVD risk scores. The impact of baseline risk on clinical event reduction by RDN-induced BP changes could be evaluated in further studies. (Global proSpective registrY for syMPathetic renaL denervatIon in seleCted IndicatIons Through 3 Years Registry; NCT01534299)
Sex, Gender, and Precision Medicine—Reply
Authors: Deborah Bartz, Hadine Joffe, JoAnn E. Manson
Journal: JAMA Internal Medicine (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Thromboelastographic Results and Hypercoagulability Syndrome in Patients With Coronavirus Disease 2019 Who Are Critically Ill
Authors: Jared Robert Mortus, Stephen E. Manek, Lisa Suzanne Brubaker, Michele Loor, Miguel Angel Cruz, Barbara W. Trautner, Todd K. Rosengart
Journal: JAMA Network Open (2020)

c Includes 1 arterial line thrombosis and 1 dialysis filter failure.d Includes 5 arterial line thromboses, 1 dialysis filter failure, and 1 arteriovenous fistula thrombosis.e Includes 7 patients with thrombotic events in more than 1 category.
Effectiveness of combination endoscopic therapy for colonic anastomotic leaks
Authors: Nikhil R. Thiruvengadam, Christopher Hamerski, Andrew Nett, Yasser Bhat, Janak Shah, Jona Bernabe, Steven Kane, Kenneth Binmoeller, Rabindra R. Watson
Journal: Endoscopy (2020)

Abstract Background Colonic anastomotic leaks are associated with significant morbidity and mortality. Whereas small case series suggest that fully covered self-expandable metal stents (FCSEMS) are effective, no larger studies have examined the impact of combination endoscopic therapy on colonic anastomotic leaks. Methods Our retrospective cohort study reviewed 51 patients undergoing endoscopic therapy for colonic anastomotic leaks between 2011 and 2018. Patients receiving combination therapy involving FCSEMS plus local closure (n = 24) were compared with patients receiving FCSEMS alone (n = 18) or endoscopic suturing alone (n = 9). The primary outcomes were technical and clinical success (resolution of leak, removal of percutaneous drains, avoidance of surgical reoperation, and reversal of temporary diversion). Results Clinical success was achieved in 55 % of patients. Clinical success was achieved in 18/24 patients (75 %) with combination therapy compared with 6/18 patients receiving FCSEMS alone (33 %, adjusted risk ratio [RR] 2.16, 95 % confidence interval [CI] 1.10 – 4.24; P = 0.02) and 4 /9 patients undergoing endoscopic suturing alone (44 %, RR 1.91, 95 %CI 0.84 – 4.31; P = 0.10). Stent migration occurred in 40 % of patients. Conclusions This large series demonstrates that combination therapy was associated with a higher rate of clinical success, and future prospective studies are warranted.
Pretreatment correlation between hemoglobin, unintentional weight loss, and inflammatory status in patient with advanced non-small cell lung cancer (NSCLC)
Authors: G. Capuano, I. Pavese, F. Satta, E. Burattini, M. Tosti, A. Palladino, M. Di Palma
Journal: Journal of Clinical Oncology (2009)

e20718 Background: Anemia, defined as a hemoglobin level &lt; 12 g/dL, is frequent in cancer and affect quality of life and performance status. Of all the pretreatment possible causes of cancer-related anemia, unintentional weight loss, early indicator of malnutrition, is often underestimated or completely ignored. The aim of this study is to evaluate the possible pretreatment correlation between hemoglobin level, recent unintentional weight loss (≥ 5% in the last three months) and inflammatory status (C-reactive protein ≥ 10 mg/dL) in NSCLC. Methods: 56 consecutive outpatients with NSCLC (IIIB - IV stage), 68% males, 32% females, were enrolled. Criteria for eligibility included absence of comorbidity (diabetes, hepatic or renal failure) and not previous oncological treatment All patients were evaluated for hemoglobin level (Hb), percentage of involuntary weight loss (WL) and C- reactive protein (CRP) before chemotherapy. Results: 25% of patients had a Hb level &lt; 12 g/dL, 38% referred a recent WL ≥ 5% and 54% had a CRP ≥ 10 mg/dL. Hb was WL-related (p = 0.001) and not CRP-related (p = 0.160), WL was CRP-related (p = 0.022). In the subgroup of patients, the differences of haemoglobin concentrations were minimal, but stastically significant only when inflammatory status was associated with WL. On Table we reported the mean concentrations of haemoglobin as measured in the subgroups of patients. Conclusions: Our data suggest that an early and intensive management of weight loss might prevent or reduce anemia in NSCLC before treatment. [Table: see text] No significant financial relationships to disclose.
Other Therapies for Sleep Apnea
Journal: American Journal of Respiratory and Critical Care Medicine (2015)

Treatment is needed for obstructive sleep apnea (OSA) because untreated OSA can result in serious health problems. Continuous positive airway pressure (CPAP) therapy is the most common treatment used for obstructive sleep apnea (OSA). (see ATS Patient Series http://patients.thoracic.org/wp-content/uploads/ 2014/03/obstructive-sleep-apnea.pdf) For those who cannot use CPAP or want to try another option, there are other therapies that can work for people with OSA.
Preventing an Acute Flaccid Myelitis Epidemic in the Time of a Pandemic
Authors: Stefanie J. Rodenbeck, Karen L. Roos
Journal: JAMA Neurology (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal
Tofacitinib for Refractory Immune-Related Colitis from PD-1 Therapy
Authors: Khashayar Esfahani, Marie Hudson, Gerald Batist
Journal: New England Journal of Medicine (2020)

Tofacitinib for Autoimmune Colitis from Anti-PD1 Tofacitinib is a JAK inhibitor that decreases cytokine production. In a woman with autoimmune colitis from the administration of pembrolizumab to tr...
Abstract A14: Modeling drug combination sensitivity with Hopfield networks and transcriptomics data
Authors: Carlo Piermarocchi, Sergii Domanskyi, Alex Hakansson, Giovanni Paternostro
Journal: Cancer Research (2020)

Abstract The Hopfield neural network model is one of the simplest models able to mathematically implement Waddington’s interpretation of normal and anomalous cell phenotypes as dynamical attractors of epigenetic landscapes. Here, we propose a computational approach based on Hopfield’s associative memories that integrate gene expression data and gene interactome networks in (1) a model representing the dynamics and control of disease progression in multiple myeloma (MM), and (2) a model describing the control of angiogenesis. The MM model is built using single-cell RNA-seq data from bone marrow aspirates of MM patients as well as patients diagnosed with monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM), two medical conditions that often progress to full MM. We identify different clusters of MGUS, SMM, and MM cells, map them to Hopfield associative memory patterns, and model the dynamics of transition between the different patterns. The model is then used to identify combinations of genes whose simultaneous inhibition is associated with delayed disease progression. In the angiogenesis control model, we use single-cell RNA-seq data to predict specific combinations of targets for inhibition that could induce a cellular transition from tip-like to stalk-like endothelial cells, inhibiting the formation of capillary sprouts in blood vessels. The model generates novel hypotheses for combinations that could complement standard VEGF inhibitors and lead to a more efficient control of angiogenesis in cancer. Citation Format: Carlo Piermarocchi, Sergii Domanskyi, Alex Hakansson, Giovanni Paternostro. Modeling drug combination sensitivity with Hopfield networks and transcriptomics data [abstract]. In: Proceedings of the AACR Special Conference on the Evolving Landscape of Cancer Modeling; 2020 Mar 2-5; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2020;80(11 Suppl):Abstract nr A14.
Minimum pricing in Scotland leads to fall in alcohol sales
Authors: Bryan Christie
Journal: BMJ (2020)

Alcohol sales from supermarkets and off-licences in Scotland fell by 4-5% in the year after minimum pricing was introduced, producing further evidence that the policy is reducing consumption.

An analysis by Public Health Scotland and the University of Glasgow1 compared data on alcohol sales with England and Wales, which do not have minimum unit pricing (MUP). It found that overall sales fell in Scotland, with the biggest reductions occurring among drinks that had been the cheapest before MUP was introduced, such as …
AB0510 INFLIXIMAB IS AN EFFECTIVE GLUCOCORTICOID-SPARING TREATMENT FOR TAKAYASU ARTERITIS: RESULTS OF A MULTICENTER OPEN-LABEL PROSPECTIVE STUDY
Authors: P. Mertz, J. F. Kleinmann, M. Lambert, X. Puéchal, T. Martin, J. Sibilia, L. Arnaud
Journal: Annals of the Rheumatic Diseases (2020)

Background: Approximately half of patients with Takayasu Arteritis (TA) have glucocorticoid (GC)-dependency and require the addition of a second-line immunosuppressive treatment. Objectives: Here, we conducted a multicenter open-label prospective cohort study to assess the efficacy and safety of infliximab originator as a GC-sparing agent in TA. Methods: A temporary recommendation for use for infliximab in refractory TA was approved by the French National Drug Authorities (April 2014). Infliximab was administered to patients in case of disease activity with a NIH score ≥2 despite conventional therapy. Data regarding patient’s clinical, laboratory, imaging and treatments were obtained at baseline, and at each following visit until last visit (October 2017). TA activity was evaluated according to NIH criteria and GC requirement throughout the study. Results: Twenty-three patients were enrolled, including 19 female. The median age at inclusion was 33 years (Interquartile range, IQR: 23-44 years). At baseline, 17 (74%) patients were treated with GCs, at a median dose of 10 mg/day (IQR: 0-21) of prednisone-equivalent. After a median follow-up of 36.9 months (IQR: 10-58.7), improvement of ≥1 NIH criterion of TA activity was achieved for 14/22 (64%) patients. The median GC dose was 8 mg/day (IQR: 7-10) at 6 months; 5 mg/day (IQR: 0-8) at 12 months and 0 mg/day (IQR: 0-5) at 36 months of follow-up. Overall, infliximab originator had a significant GC-sparing effect between baseline and last follow-up ( p =0.009). Conclusion: This multicenter open-label cohort study suggests that infliximab originator is an effective GC-sparing treatment for TA refractory to conventional therapy. Disclosure of Interests: None declared
AB0419 THE COEXISTENCE OF FAMILIAL MEDITERRANEAN FEVER (FMF) IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) PATIENTS - A CROSS SECTIONAL STUDY
Authors: T. Klein, S. Tiosano, A. Chohen, H. Amital
Journal: Annals of the Rheumatic Diseases (2020)

Background: Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease characterized by multisystem inflammatory lesions affecting many organ systems in the body. Familial Mediterranean fever (FMF) is an autosomal recessive disease of chronic autoimmune inflammation characterized by frequently relapsing self-limiting fever and inflammation that may be localized in peritoneum, pleura, joint or skin. 1 Previous studies have described the similarity of clinical symptoms of FMF among SLE patients. However, the literature on this topic is inconsistent and based mostly on case reports. 2-4 Objectives: To examine the proportions of coexistence of FMF among SLE patients compared to the general population. We hypothesized that the proportion of FMF among SLE patients is higher than the general population. Methods: This cross-sectional study used the Clalit Health Services database, the largest Health Maintenance Organization in Israel, serving 4,400,000 members. SLE patients were compared to age- and sex-matched controls. Chi- was used for univariate analysis. Results: The study included 4886 SLE patients and 24430 age- and sex-matched controls. The SLE group had a significantly higher proportion of FMF patients compared to non-SLE controls (0.68% and 0.21% respectively; p &lt; 0.001). Table 1. All study population Table 1. SLE patients and matched controls basic characteristics No SLE SLE p.overall N=24430 N=4886 Age 51.2±16.5 51.2±16.5 1.000 Gender: Female 20100 (82.3%) 4020 (82.3%) 1.000 FMF 52 (0.21%) 33 (0.68%) &lt;0.001 Table 2. Stratification Table 2. comparison of FMF patients with and without SLE FMF without SLE FMF with SLE p.overall N=52 N=33 Age 44.6±13.7 50.5±17.7 0.106 Gender: Female 45 (86.5%) 26 (78.8%) 0.523 Conclusion: FMF was found to be more common amongst SLE patients compared to matched controls.The current study results suggest that the occurrence of SLE turn patients with an appropriate genetic and environmental setting to develop also FMF. This cross-sectional study sheds light on the coexistence of these two diseases, autoimmune and autoinflammatory. References: [1]Kucuk A, Gezer IA, Ucar R, Karahan AY. Familial mediterranean fever. Acta Medica (Hradec Kralove ). 2014;57(3):97-104. [2]Lidar M, Zandman-Goddard G, Shinar Y, Zaks N, Livneh A, Langevitz P. SLE and FMF: A possible negative association between the two disease entities–report of four cases and review of the literature. Lupus . 2008;17(7):663-669. [3]Erten S, Taskaldiran I, Yakut ZI. Are systemic lupus erythematosus patients carrying MEFV gene less prone to renal involvement? report of three cases and review of the literature. Ren Fail . 2013;35(7):1013-1016. [4]Shinar Y, Kosach E, Langevitz P, et al. Familial mediterranean Fever gene (MEFV) mutations as a modifier of systemic lupus erythematosus. Lupus . 2012;21(9):993-998. Disclosure of Interests: : None declared